UK MHRA Adapts Inspections Program To Account For Increase In Pharmacovigilance Outsourcing
Executive Summary
As drug companies increasingly outsource their pharmacovigilance activities to third party organizations, the UK regulator has made changes to its inspections program so that all affected marketing authorization holders are kept abreast of any problems identified at contract service providers.
You may also be interested in...
UK MHRA Pilot To Explore Benefits Of Standalone Inspections For Pharmacovigilance Service Providers
The UK Medicines and Healthcare Products Regulatory Agency has launched a pilot to ascertain whether the introduction of a new standalone program, under which it would inspect pharmacovigilance service providers, could cut inspection costs incurred by drug companies that use these third-party organizations and also save agency resources.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.